But now, theyre widely prescribed for those with obesity or weight-related health conditions (even if diabetes isnt part of the picture)
To view or add a comment, sign in Eisai and Biogen are developing a new version of their Alzheimers drug, LEQEMBI IQLIK, that patients could inject at home
Risk Factors Requiring Elevated Screening Personal history of any eating disorder, including sub-threshold presentations, adolescent dieting pathology, or ARFID Family history of restrictive eating, excessive exercise, or diet-culture-driven food restriction High dietary restraint, rigid food rules, or BMI-focused identity Any prior mental health diagnosis doubles two-year eating disorder risk post-initiation Adolescent and young adult patients developmentally most vulnerable Off-label use in patients without metabolic comorbidities the cosmetic use population most likely to include subclinical disordered eating What the Physiology Actually Produces in a Restrictive Mind For a patient with anorexia nervosa in whom the ego-syntonic experience of not being hungry is already rewarding GLP-1-mediated appetite suppression does not feel like a side effect to manage
This widespread receptor activation, combined with rapid changes in blood glucose and hydration status during early treatment, can provoke headaches in susceptible individuals
The move should draw the attention of pharma marketers navigating obesity and metabolic drug promotion
